HANSOH PHARMA | AMEILE’S FIFTH INDICATION FOR “TARGETED THERAPY PLUS CHEMOTHERAPY” APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA’S ORIGINAL THIRD-GENERATION EGFR-TKI
On January 6, 2026, Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma," 03692.HK) announced that a new indication of Ameile (Aumolertinib Mesylate...
2026.01.12